Notice of the Convening of the Annual General Meeting of Diagnostyka S.A.

Date: 28 April 2026

Subject: Notice of the Convening of the Annual General Meeting of Diagnostyka S.A.

Legal basis: Article 56(1)(2) of the Act on Public Offering – current and periodic information

Text of the report:

The Management Board of Diagnostyka S.A. (the “Company”), acting pursuant to Article 399 § 1 of the Commercial Companies Code, hereby resolves to convene the Annual General Meeting of the Company for 25 May 2026 at 14:00, in Kraków, at the Aquarius building, 18 Życzkowskiego Street.

The following agenda has been adopted:

1. Opening of the Annual General Meeting.
2. Election of the Chairperson of the Annual General Meeting.
3. Confirmation that the Annual General Meeting has been duly convened and is capable of adopting binding resolutions.
4. Adoption of the agenda.
5. Review of the reports of the Company’s governing bodies, the Company’s financial statements and the consolidated financial statements for 2025.
6. Adoption of a resolution on the approval of the Company’s financial statements for 2025.
7. Adoption of a resolution on the approval of the consolidated financial statements of the Diagnostyka Group for 2025.
8. Adoption of a resolution on the approval of the Management Board’s Report on the Operations of Diagnostyka S.A. and the Diagnostyka Capital Group for the 2025 financial year (including the Management Board’s report on the operations of the parent company – Diagnostyka S.A. – and the sustainability reporting of the Diagnostyka Capital Group for 2025).
9. Adoption of a resolution on the distribution of the Company’s profit for 2025.
10. Adoption of a resolution on granting discharge to Mr Jakub Swadźba, President of the Management Board, in respect of the performance of his duties for the period from 1 January to 31 December 2025.
11. Adoption of a resolution on granting discharge to Mr Dariusz Zowczak, Vice President of the Management Board, in respect of the performance of his duties for the period from 1 January to 31 December 2025.
12. Adoption of a resolution on granting discharge to Ms Marta Rogalska-Kupiec, Vice President of the Management Board, in respect of the performance of her duties for the period from 1 January to 31 December 2025.
13. Adoption of a resolution on granting discharge to Mr Paweł Chyła, Vice President of the Management Board, in respect of the performance of his duties for the period from 1 January to 31 December 2025.
14. Adoption of a resolution on granting discharge to Mr Jaromir Pelczarski, Vice President of the Management Board, in respect of the performance of his duties for the period from 1 January to 31 December 2025.
15. Adoption of a resolution on granting discharge to Mr Artur Olender, Chairperson of the Supervisory Board, in respect of the performance of his duties for the period from 1 January to 31 December 2025.
16. Adoption of a resolution on granting discharge to Mr Jacek Prusek, Member of the Supervisory Board, in respect of the performance of his duties for the period from 1 January to 31 December 2025.
17. Adoption of a resolution on granting discharge to Mr Grzegorz Głownia, Member of the Supervisory Board, in respect of the performance of his duties for the period from 1 January to 31 December 2025.
18. Adoption of a resolution on granting discharge to Mr Marcin Fryda, Member of the Supervisory Board, in respect of the performance of his duties for the period from 1 January to 31 December 2025.
19. Adoption of a resolution on granting discharge to Ms Aniela Hejnowska, Member of the Supervisory Board, in respect of the performance of her duties for the period from 1 January to 31 December 2025.
20. Adoption of a resolution on granting discharge to Mr Paweł Malicki, Member of the Supervisory Board, in respect of the performance of his duties for the period from 1 January to 28 April 2025.
21. Adoption of a resolution on granting discharge to Mr Matthew Strassberg, Member of the Supervisory Board, in respect of the performance of his duties for the period from 1 January to 28 April 2025.
22. Adoption of a resolution on granting discharge to Mr Paweł Leżański, Member of the Supervisory Board, in respect of the performance of his duties for the period from 28 April to 31 December 2025.
23. Adoption of a resolution on granting discharge to Mr Piotr Solorz, Member of the Supervisory Board, in respect of the performance of his duties for the period from 28 April to 31 December 2025.
24. Adoption of a resolution on granting discharge to Ms Patrycja Swadźba, Member of the Supervisory Board, in respect of the performance of her duties for the period from 28 April to 31 December 2025.
25. Adoption of a resolution on the approval of the annual report of the Company’s Supervisory Board for 2025.
26. Adoption of a resolution on the merger with the Company’s subsidiary, Laboratoria Medyczne NOVALAB sp. z o.o., with its registered office in Suwałki.
27. Closing of the Annual General Meeting.

Attached to this report, the Company provides the notice of the convening of the Annual General Meeting prepared in accordance with Article 402² of the Commercial Companies Code, together with the draft resolutions to be considered at the meeting, as well as the resolution of the Supervisory Board on the adoption of the Supervisory Board’s report for 2025 (the approval of which is included in the agenda).

The Company notes that the resolutions of the Supervisory Board concerning the assessment of the Company’s financial statements (standalone and consolidated) and the assessment of the Management Board’s report on the operations of the Company and the Capital Group, as well as the resolution of the Supervisory Board concerning its opinion on the Management Board’s recommendation regarding the distribution of profit for 2025, were previously made public. This was done, respectively, together with the periodic reports (the consolidated annual report – CAR and the annual report – AR) and Current Report No. 3/2026.

The remaining documents were previously made available on the Company’s website, www.grupadiagnostyka.pl/dla-inwestorow/, in the “Periodic Reports” section.

Legal basis: § 20(1)(1) and (2) of the Regulation of the Minister of Finance of 6 June 2025 on current and periodic information provided by issuers of securities and conditions for recognising as equivalent information required under the laws of a state that is not a Member State.

For the Company:

Marta Rogalska-Kupiec – Vice President of the Management Board

Dariusz Zowczak – Vice President of the Management Board